456 related articles for article (PubMed ID: 12234992)
1. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
2. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
4. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of DNA replication by tirapazamine.
Peters KB; Wang H; Brown JM; Iliakis G
Cancer Res; 2001 Jul; 61(14):5425-31. PubMed ID: 11454687
[TBL] [Abstract][Full Text] [Related]
6. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
Delahoussaye YM; Hay MP; Pruijn FB; Denny WA; Brown JM
Biochem Pharmacol; 2003 Jun; 65(11):1807-15. PubMed ID: 12781332
[TBL] [Abstract][Full Text] [Related]
7. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
8. Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine.
Shin HJ; Kim JY; Yoo CW; Roberts SA; Lee S; Choi SJ; Lee HY; Lee DH; Kim TH; Cho KH
J Cancer Res Clin Oncol; 2008 Mar; 134(3):397-404. PubMed ID: 17724612
[TBL] [Abstract][Full Text] [Related]
9. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
10. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract][Full Text] [Related]
11. QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells.
Chen MC; Pan SL; Shi Q; Xiao Z; Lee KH; Li TK; Teng CM
Cancer Sci; 2012 Jan; 103(1):80-7. PubMed ID: 21920000
[TBL] [Abstract][Full Text] [Related]
12. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
13. Suppression of hypoxia-inducible factor 1α (HIF-1α) by tirapazamine is dependent on eIF2α phosphorylation rather than the mTORC1/4E-BP1 pathway.
Zhang J; Cao J; Weng Q; Wu R; Yan Y; Jing H; Zhu H; He Q; Yang B
PLoS One; 2010 Nov; 5(11):e13910. PubMed ID: 21085474
[TBL] [Abstract][Full Text] [Related]
14. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
Eijdems EW; de Haas M; Timmerman AJ; Van der Schans GP; Kamst E; de Nooij J; Astaldi Ricotti GC; Borst P; Baas F
Br J Cancer; 1995 Jan; 71(1):40-7. PubMed ID: 7819046
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of Tirapazamine (3-Amino-1,2,4-benzotriazine-1,4-dioxide)-Induced DNA Damage in Chicken DT40 Cells.
Moriwaki T; Okamoto S; Sasanuma H; Nagasawa H; Takeda S; Masunaga SI; Tano K
Chem Res Toxicol; 2017 Feb; 30(2):699-704. PubMed ID: 27943678
[TBL] [Abstract][Full Text] [Related]
16. Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone.
Smart DJ; Halicka HD; Schmuck G; Traganos F; Darzynkiewicz Z; Williams GM
Mutat Res; 2008 May; 641(1-2):43-7. PubMed ID: 18423498
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
[TBL] [Abstract][Full Text] [Related]
18. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
[TBL] [Abstract][Full Text] [Related]
19. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
Wouters BG; Wang LH; Brown JM
Ann Oncol; 1999; 10 Suppl 5():S29-33. PubMed ID: 10582136
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
